Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I've discovered this company and really like it. looks like MIGI is trading at less than half of book. And the don't just mine but sell power during spikes. $ 4 million in revs just doing that in the month of December. News today that look promising. https://finance.yahoo.com/news/mawson-infrastructure-group-inc-expands-133000670.html
” The need to find alternative nondrug means of treating patients’ pain is paramount, especially during times of crisis. Clinicians need to be open to these complementary and alternative therapies and accept them as valid alternatives.
Of importance, it may increase calls for insurance companies to cover these treatments and for future providers to specialize in their administration. “That could really be a silver lining here. If clinicians are motivated to find someone in the community that employs biofeedback, relaxation or mindfulness meditation, patients may be able to lower or eliminate their need for controlled substance medications. That’s a big piece that’s missing,” Gudin told Pain Medicine News. “We know it works. We know if you get patients to think positively about their pain, they actually feel better. Everybody wants it, but not many know enough about it or are willing to pay for it.”
https://mail.google.com/mail/u/0/#inbox/WhctKJWQfjwcvBwVPBSptXHCWDsnlRDsnMcRHlvfKBQGMGQTllFMBjqWcHRTnZXscdTqfKG
I agree. But it may in the future.I'm not privy to any new research information.
Thanks for the information. My experience has been that nothing is working that great and ofcourse doctors recommend pills. They do the same thing for all chronic pain. How is that working? Not very well. This particular patient had been to every reputable migraine clinic in the country and NOTHING but Calmare worked.
Jan 19
New patient Shar adds her pin to our Calmare global map. Battling #arachnoiditis for 4 years, a severe #chronicpain disorder, her pain has reduced from a 9.5 to a 2.5 after two Calmare sessions. And we're not done yet. #neuropathy #Calmare #waronpain
This might be a break through. Look at this post on Facebook talking about Calmare:
Kathleen Hansen
It has saved our granddaughter who suffered immensely with chronic migraines!! Thank you Tom for introducing this machine to her????????
How big ia that market?
Migraine Statistics
By Editorial Team · November 30, 2010
SHARE
In the U.S., more than 38 million people have migraine disease, with some estimates suggesting that this number may be even higher, impacting as many as 50 million or more. Some migraine studies estimate that 12 percent of adults in the U.S. population have migraine, and 4 million have chronic migraine.1,2
Most individuals in the U.S. with migraine experience one to two migraine attacks per month, however, those with chronic migraine may have 15 migraine days, or more, per month. Approximately 9 out of every 10 people with migraine cannot function normally during an attack, and roughly one in five are disabled.2
The NO Pain Act This may be the key to Medicare covering Calmare: https://www.congress.gov/bill/116th-congress/house-bill/5172/text
GLOBAL PAIN RELIEF THERAPY MARKET (COVID 19 UPDATE) ADMIRABLE GROWTH ANALYSIS BY PRODUCT TYPE, APPLICATIONS, REGIONAL OUTLOOK, TECHNOLOGY, OPPORTUNITY 2020 – 2027
Posted On: October 1, 2020 Posted By: Sopan Comments: 0
DBMR has added a new report titled Global Pain Relief Therapy Market with analysis provides the insights which bring marketplace clearly into the focus and thus help organizations make better decisions. The data and the information regarding the industry are taken from consistent sources such as websites, annual reports of the companies, and journals which is then checked and validated by the market experts. Global Pain Relief Therapy Market report has been structured with transparent research studies which makes it of supreme quality. By exactly understanding customer requirement, one or more methods are used to construct this finest market research report. The report provides with CAGR value fluctuation during the forecast period of 2020 – 2027 for the market.
Global Pain Relief Therapy Market is expected to rise from its initial estimated value of USD 1117.61 billion in 2016 to an estimated value of USD 1,849.63 billion by 2026, registering a CAGR of 6.5%in the forecast period of 2016-2026. Increasing investment on R&D is driving the growth of this market.
Download PDF Sample Copy of Report@ http://databridgemarketresearch.com/request-a-sample/?dbmr=global-pain-relief-therapy-market
Key Market Competitors: Global Pain Relief Therapy Market
Some of the major players operating in global pain relief therapy market are Johnson & Johnson Services, Inc., Eli Lilly & Company, Merck & Co. Inc., Pfizer, Inc., Abbott, F. Hoffmann La Roche Ltd., DJO, LLC, Breg, Inc., Beiersdorf AG, Medline Industries, Inc., 3M, Sanofi, ROHTO Pharmaceutical Co., Ltd., Össur Americas, Hisamitsu Pharmaceutical Co., Inc., Calmar Pain Relief, LLC, UltraCare PRO, Polar Products Inc., Agm Overseas, Stimwave LLC, Neurometrix, Niagara, Calmare Therapeutics Incorporated, Iskra Medical d.o.o., THERALASE Technologies Inc., Sombra Professional Therapy Products, Good Health Naturally, Endo Pharmaceuticals Inc., BioElectronics Corporation, HYH, Danaher, ALLERGAN, Purdue Pharma among others
Report Segmentation
Global Pain Relief Therapy Market By Products (Prescription based products, OTC-based products {Pharmaceuticals, Medical Devices}), Mode of Purchase (Over-The-Counter, Prescribed), Application (Musculoskeletal Disorder, Sport Medicine, Post-operative, Post-trauma, Physical Therapy), End-User (Hospitals, Clinics, Ambulatory Centers, Physiotherapy Centers, Homecare Settings), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) – Industry Trends and Forecast to 2026
Market Definition: Global Pain Relief Therapy Market
Pain is complex and its medication is of various types, natural pain may occur due to natural lifestyle changes, pain may occur due to several reasons eg; Injuries, chronic diseases.
Pain is an intensely unpleasant sensory nervous system’s mechanism to alert the brain that action must be taken as quickly as possible to protect the body from various symptoms.
Market Drivers
The advancements of large untapped markets, drug development in the developing economies are anticipated to provide new avenues for the industry growth in the near future.
Due to growing awareness about potential implications of prolonged use of pain treatment drugs, including reduced efficacy, risk of addiction and side effects is going to drive the market growth
Market Restraints
Potential restraints of the global pain relief market are skin irritation, burning sensation and allergic reactions due to over usage of pain relievers.
Competitive Analysis:
Global pain relief therapy market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of pain relief therapy market for Global, Europe, North America, Asia Pacific, South America and Middle East & Africa.
Key Benefits
The study provides an in-depth analysis of the Pain Relief Therapy market size along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the predominant Pain Relief Therapy market opportunities.
• A comprehensive analysis of all the geographical regions is provided to determine the prevailing opportunities.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global Pain Relief Therapy market.
The Global Pain Relief Therapy Market is highly fragmented and is based on new product launches and clinical results of products. Hence the major players have used various strategies such as new product launches, clinical trials, market initiatives, high expense on research and development, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of pain relief therapy market for global, Europe, North America, Asia Pacific and South America.
Inquire Regarding This Report @ https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-pain-relief-therapy-market
I'm waiting and watching just like the rest of you. Stock is acting well. I saw a 700,000 bid in the stock today.
I'm cautiously watching to see if we get some gov. revenues before the end of Sept. and 2.7 million by the end of the year as projected. If those numbers come to pass than those future expectations become more realistic. Did you notice we had 1.2 million in revs in 2019? I think that was accurate. So let's see what happens. If he's right with his projections we should have a $20 plus stock in two years. From my lips to God's ears.
BC/BS in Michigan lost an appeal recently for not paying for Calmare. The Michigan Dept. of Insurance ruled the peer reviewed literature over the past 8 to 10 years supports positive study results on a variety of pain management types. This device is more likely than not to be better than the current standard of care.
We open on a 134 share sell at .063? Who does that? Manipulator? That can't be a real trade for less than $10.
I think the key here is this:
"This is a great accomplishment for the Company," said Calmare Therapeutics President & CEO Conrad Mir. "Our team has worked diligently to reach this goal. We anticipate delivering on this contract and posting revenues in short order."
So last time they didn't deliver. Let's see if something happens here in "posting revenues in short order"
I expect most of these questions will be answered with updated financials. I expect that will happen in the 3rd quarter according to the CFO.
Video Testimonials from just one Calmare doctor!
https://www.youtube.com/user/CalmareTherapyNJ/videos via Calmare NJ
Discussion
The results of this sham-controlled trial in patients with
NMOSD demonstrate that Scrambler therapy is an acceptable,
feasible, and safe intervention for central neuropathic pain, with
evidence that supports efficacy. Participants who received
Scrambler therapy had a significant reduction in pain compared
to those who received sham treatment. This was sustained at 30
days after the treatment course. Notably, there was no differ-
ence in the number of patients who thought they were assigned
to the treatment vs sham groups, which suggests that any
placebo effect was controlled for through the established sham
intervention. To date, most research investigating the effect of
Scrambler therapy on pain has involved open-label trials for
peripheral neuropathic pain management.12–15,33,34 Four
studies have used a random controlled design, including 2
unblinded prospective randomized trials that tested Scrambler
against an active comparator30,35 and 2 that have applied
a blinded randomized sham-controlled design. One involved
patients with chemotherapy-induced peripheral neuropathy,
which found no difference compared to Scrambler therapy
placed on the back near the spine (n = 14).36 In a second
prospective placebo-controlled trial in patients diagnosed with
low-back pain (n = 30), the treatment group was found to have
a significant reduction in pain compared to the control group.37
The sham group received Scrambler therapy at what was
thought to be subtherapeutic doses.
Results suggest that the trial is feasible and acceptable. Ad-
herence with the full program comprising 10 sequentialdesign to mitigate the risk of confounding effects from pain
medication class on the basis of previous data that reported
that the type of medication may be predictive of response to
Scrambler therapy,23 our study was not powered to suffi-
ciently compare efficacy results across classes of pain
medications because patients were often on multiple med-
ications. The effect that modifying pain through Scrambler
therapy had on co-occurring symptoms was also limited by
the sample size.
Lastly, while it was encouraging that a difference was detected
between the Scrambler-treated and sham arms, this study was
not powered to effectively examine sustainability of treatment
through the 60-day follow-up period. The practicality of using
Scrambler increases if the effect is sustained. The trend toward
significance at 60 days suggests that a larger study that
includes 29 patients per arm may uncover sustained effect.
Furthermore, re-emergence of pain in treatment of both
central and peripheral pain conditions has been described,18,19
and pain has been shown to be amenable to subsequent
booster treatments, often with fewer Scrambler treatment
sessions needed.12 Anecdotally, 1 complete responder from
the current study was subsequently treated when pain began
to re-emerge after study completion and remains pain-free
months later. Thus, adapting the protocol to include sub-
sequent booster treatments when pain emerges should be
considered for future studies. Overall, the effectiveness, fea-
sibility, and safety profiles we report support the need for
a larger phase III study to further examine the effect of
Scrambler on pain, reduction of analgesic medication use, co-
occurring symptoms, and QoL in a larger NMOSD patient
cohort.
Posting study results isn't hype. most people who own the stock appreciate the information because you won't hear it from the company. The latest study may be the most significant yet: Controlled single-blinded study with a sham device with great results. It was published in May 5th in the Journal: NEUROLOGY
Scrambler therapy improves pain in
neuromyelitis optica
A randomized controlled trial
Maureen A. Mealy, PhD, RN, Sharon L. Kozachik, PhD, RN, FAAN, Lawrence J. Cook, PhD, Lauren Totonis, MSN,
Ruth Andrea Salazar, MD, Jerilyn K. Allen, ScD, RN, Marie T. Nolan, PhD, RN, FAAN, Thomas J. Smith, MD, and
Michael Levy, MD, PhD
Neurology® 2020;94:1-e8. doi:10.1212/WNL.0000000000009370
Abstract
Objective
To determine whether Scrambler therapy is an effective, acceptable, and feasible treatment of
persistent central neuropathic pain in patients with neuromyelitis optica spectrum disorder
(NMOSD) and to explore the effect of Scrambler therapy on co-occurring symptoms.
Methods
We conducted a randomized single-blind, sham-controlled trial in patients with NMOSD who
have central neuropathic pain using Scrambler therapy for 10 consecutive weekdays. Pain
severity, pain interference, anxiety, depression, and sleep disturbance were assessed at baseline,
at the end of treatment, and at the 30- and 60-day follow-up.
Results
Twenty-two patients (11 per arm) were enrolled in and completed this trial. The median
baseline numeric rating scale (NRS) pain score decreased from 5.0 to 1.5 after 10 days of
treatment with Scrambler therapy, whereas the median NRS score did not significantly decrease
in the sham arm. Depression was also reduced in the treatment arm, and anxiety was decreased
in a subset of patients who responded to treatment. These symptoms were not affected in the
sham arm. The safety profiles were similar between groups.
Conclusions
Scrambler therapy is an effective, feasible, and safe intervention for central neuropathic pain in
patients with NMOSD. Decreasing pain with Scrambler therapy may additionally improve
depression and anxiety.
Clinicaltrials.gov identifier
NCT03452176.
Classification of evidence
This study provides Class II evidence that Scrambler therapy significantly reduces pain in
patients with NMOSD and persistent central neuropathic pain.
Results of a new study from Johns Hopkins! https://clinicaltrials.gov/ct2/show/NCT03452176
Calmare Pain Therapy makes the list:
https://www.openpr.com/news/2037967/global-pain-relief-therapy-market-showing-growth-with-top
Calmare NJ is at VA New Jersey Health Care System. East Orange, NJ ·
Some great news for veterans in the Veteran's Administration Northeast District!
Calmare, a non-invasive therapy to combat chronic pain, is now a VA-approved in-network provider, with a written referral from a VA hospital.
Details: https://calmaretherapynj.com/…/dr-michael-cooney-is-now-a-…/ via VA New Jersey Health Care System Tinton Falls Northport VA Medical Center VA Western New York Healthcare System
Medicare is now covering acupuncture after all these years. A change in heart by the FDA for paying for alternatives to drugs for treating pain?
https://www.painmedicinenews.com/Online-First/Article/01-20/Medicare-to-Cover-Acupuncture-for-Low-Back-Pain/57164?sub=--esid--&enl=true&dgid=--DGID--&utm_source=enl&utm_
Many doctors have stopped prescribing opioids. They have to fill the gap with something!
https://local21news.com/news/the-opioid-crisis-finding-hope/growing-number-of-doctors-no-longer-prescribing-opioids
On=the=other hand there continues to be more spending for our VETS healthcare. And more money fighting opiods and finding substitutions fighting opioids.
https://www.marketwatch.com/press-release/global-pain-relief-therapy-market-is-on-the-rise-with-top-players-like-ohnson-johnson-services-inc-eli-lilly-company-merck-co-inc-pfizer-inc-abbott-f-hoffmann-la-roche-ltd-2020-01-13
Some of the major players operating in global pain relief therapy market are Johnson and Johnson Services, Inc., Eli Lilly and Company, Merck and Co. Inc., Pfizer, Inc., Abbott, F. Hoffmann La Roche Ltd., DJO, LLC, Breg, Inc., Beiersdorf AG, Medline Industries, Inc., 3M, Sanofi, ROHTO Pharmaceutical Co., Ltd., Össur Americas, Hisamitsu Pharmaceutical Co., Inc., Calmar Pain Relief, LLC, UltraCare PRO, Polar Products Inc., Agm Overseas, Stimwave LLC, Neurometrix, Niagara, Calmare Therapeutics Incorporated, Iskra Medical d.o.o., THERALASE Technologies Inc., Sombra Professional Therapy Products, Good Health Naturally, Endo Pharmaceuticals Inc., BioElectronics Corporation, HYH, Danaher, ALLERGAN, Purdue Pharma among others
New CRPS Book Features Calmare Therapy and Dr. Michael Cooney
January 29, 2020
CRPS book features calmare therapy
Our clinical director, Dr. Michael Cooney, who has successfully treated hundreds of people living with CRPS since 2011 using Calmare scrambler therapy, is featured in a new book on the topic,
COMPLEX REGIONAL PAIN SYNDROME (CRPS): PATIENTS’ PERSPECTIVE OF LIVING IN CHRONIC PAIN.
The book is co-written by pain management physician specialist Dr. Alaa Abd-Elsayed and Eric M. Phillips, president of The International Research Foundation For RSD / CRPS.
One of our teen patients, Austin, is featured. His parents describe his significant pain relief (and leg lesion healing) after Calmare Therapy and booster treatments:
CRPS book features Dr. Michael Cooney
Teen Football Star Finds CRPS Pain Relief After Calmare Therapy
We are grateful to Austin’s family, who volunteered to share their family’s story and Austin’s positive outcome after Calmare Therapy.
Austin did return months later for three scrambler therapy booster treatments, which may be necessary for more severe or prolonged cases of chronic nerve pain.
He shared an update from the mountains (where he was snowboarding!) in February 2019:
Teenager Snowboards By for a Post-Calmare Scrambler Therapy Update
Austin and Dr. Michael Cooney celebrate his success after undergoing Calmare scrambler for CRPS.
“I was honored to be included in a truly comprehensive book about the challenges faced by so many courageous people around the world living with CRPS,” says Dr. Cooney.
“It is vitally important that sufferers understand that drugs and invasive procedures are not the only way to reduce pain from this disease.”
CRPS book features calmare therapy
Scrambler Therapy: Drug-Free, Non-Invasive Pain Management for Chronic Nerve Pain
Dr. Michael Cooney treats people with pain with a refreshingly personal approach–he talks to you before you ever step foot into our New Jersey clinic.
Calmare Therapy, cleared by the FDA more than a decade ago, is not right for everyone suffering from CRPS or other conditions resulting in chronic nerve pain.
If you are able to travel to our clinic, located in New Jersey, USA, 15 minutes outside New York City, we invite you to complete the Consult Request form below.
All fair points. But what does that mean to the stock and the future? Everything you mentioned is already discounted. A lot of room for upside surprises. No reporting doesn't mean there are no sales going on. Just in the Atlanta area there have been 3 sales in the past month or so. There have been multiple sales in South Carolina as well. These are all new clinics. There is a new clinic in North Carolina, Maryland, Michigan, Utah, Memphis and Phoenix. Bottom line there is now a Calmare Clinic closer to your home. I spoke with the CFO and the company plans on getting year-end numbers out and their financial reporting back on track.
The difference is fact vs.hype. Over 50 insurance companies now have paid for Calmare. And now the largest insurance company in the State of Michigan BCBS now pays for Calmare.
That's correct. The largest insurance provider in The State of Michigan.
I agree and it's happening. The Dept. of Insurance in Michigan just had a significant ruling requiring BCBS to pay for Calmare. They are the largest Healthcare Insurance provider in the state.
Great Article on Insurance needs to pay for non-pharma alternatives to opioids"
https://www.tribtoday.com/news/local-news/2020/01/chiropractor-says-med-free-options-still-not-available/
Some efforts have been made to curb the overprescribing of opioids in hospital settings, but little has been done to guarantee health care facilities and insurance plans are using and covering the medication-free interventions that have been proven to keep a person off the gateway drugs that can eventually lead to illicit use, said Dr. Patrick Ensminger
The restrictions on the prescriptions — without plans to wean a patient off the meds or to replace the treatment with a medication-free option, like physical therapy or chiropractic therapy — may have driven more opioid users to the streets, he said.
American patients were 70 times more likely to be prescribed an opioid than a person seeing a doctor in Europe.
The report found “U.S. physicians are still dramatically overprescribing opioids for pain, rather than referring cases to drug-free health care providers,” Ensminger said.
Methods to reduce the prescriptions often lead to just pushing back the time it takes for the physician to give an opioid, or replacing the opioid with a similar drug.
“That opioids are still actually commonly prescribed for run of the mill musculoskeletal pain is not progress,” Ensminger said. “Right now, the MD might say, ‘I don’t do opioids anymore, so I’m going to send you to pain management or I’m going to send you to an orthopaedic specialist.’ Guess what they’re going to get there? ‘Well, you don’t qualify for surgery, so here’s a course of opioids, go to the pain management.’ And the, ‘Well we tried an epidural and it didn’t work, so here’s some opioids.’ So they still end up getting that kind of management, it’s just being pushed upstream.”
And the opioids don’t treat the underlying issue; they cloud the pain of an issue. Physical therapy and chiropractic work may have a chance at eliminating the problem after a treatment plan is implemented and followed, Ensminger said.
These practices continue in health care facilities, despite federal and state guidelines that recommend the alternative treatments, Ensminger said.
A study of over 200,000 patients with first time back pain found if someone saw a chiropractor before an MD, 90 percent were less likely to get prescribed an opioid than if he or she saw a doctor first, said Ensminger, referring to the study published in BMJ Open, a national medical journal.
“Our doctors are well meaning and want to do the right thing for their patients but they are stuck in an American health care culture where there’s a drug for everything. The United States spends more than twice as much per capita on health care as other developed nations and yet we rank a disappointing 37th in overall health globally,” Ensminger said.
Efforts to negotiate with insurance companies and health care facilities has led to little change, he said.
Ohio chiropractors want a “seat at the table” with regulators and insurance companies as they create rules and plans for the future because they want to help people with chronic pain in a way that doesn’t endanger their patient with addiction, Ensminger said.
Changing the price structures of the insurance plans can lead to a real change in what services people opt for and has a chance of changing the culture surrounding pain treatment in the U.S., he said.
Another article of shocking news. https://www.newsmax.com/health/health-news/legalized-recreational-marijuana-pot-use/2019/11/14/id/941644/
Will the madness ever stop?
Opioid and Cannabis Co-Use for Chronic Pain Elevates Risk for Mental Health Issues
https://www.painmedicinenews.com/Clinical-Pain-Medicine/Article/12-19/Opioid-and-Cannabis-Co-Use-for-Chronic-Pain-Elevates-Risk-for-Mental-Health-Issues/56779?sub=A21642F22545E1D4
I find it so interesting with this opioid crisis every competing product with Calmare is having issues.
Injections:https://www.thedoctorstv.com/videos/are-steroid-injections-doing-more-harm-than-good
Anticonvulsants: https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin
Spinal Stimulators: https://www.statnews.com/2018/11/25/medical-devices-pain-other-conditions-more-than-80000-deaths-since-2008/
Pain Pumps: https://www.statnews.com/2018/11/25/medical-devices-pain-other-conditions-more-than-80000-deaths-since-2008/
Calmare has no side effects!
You are dead right. My point is if that changes it's not reflected in the current price. A 5 million market cap reflects no expectations. I predict we will see changes ahead.I expect a 10-K will be filed for year-end 2019. And if I'm right the upside is significant.
CNBC Today. In the past five years 7 out 10 of the top gainers have been medical device companies, and they are recession resistant. The valuation of Calmare is ridiculous. IMO If it was an IPO and they were current on their financials it would have a market cap of several hundred million dollars. (they can get current on their financials) IMO